Drug Trial Radar · NCT06773910
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Mar 11, 2025
Primary completion
May 2032
Study completion Sep 2032
Sponsor
- Lead sponsor
- SCRI Development Innovations, LLCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bristol-Myers Squibb
- First posted
- Jan 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489
Conditions
- Limited Stage Small Cell Lung Cancer
Interventions
BMS-986489Drug
BMS-986489 (fixed dose combination of atigotatug + nivolumab) will be administered as an intravenous infusion to be given once every 4 weeks for up to 2 years.
DurvalumabDrug
Durvalumab will be administered as a fixed dose intravenous infusion to be given once every 4 weeks for up to 2 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the efficacy of BMS-986489 vs durvalumab by Overall Survival (OS).Time frame: From date of randomization up to 5 years. Every 8 weeks for participants who stopped treatment before disease progression and before completing 6 months of treatment and every 12 weeks for participants who stopped treatment before disease progression and
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Southern Cancer Center
Daphne, Alabama
Sansum Clinic
Santa Barbara, California
Florida Cancer Specialists - South
Fort Myers, Florida
University of Miami - Sylvester Cancer Center
Miami, Florida
Ocala Oncology Center
Ocala, Florida
Florida Cancer Specialists - North
Orange City, Florida
Cancer Care Centers of Brevard
Palm Bay, Florida
Florida Cancer Specialists - East
West Palm Beach, Florida
Piedmont Healthcare - Atlanta
Atlanta, Georgia
Illinois Cancer Specialists
Arlington Heights, Illinois
Illinois Cancer Care
Peoria, Illinois
Indiana University Simon Cancer Center
Indianapolis, Indiana
Baptist Health - Corbin
Corbin, Kentucky
Baptist Health - Lexington
Lexington, Kentucky
Baptist Health - Louisville
Louisville, Kentucky
Minnesota Oncology Hematology
Maple Grove, Minnesota
Missouri Cancer Associates
Columbia, Missouri
White Plains Hospital Physician Associates
White Plains, New York
Carolina Cancer Research Center
Wilson, North Carolina
Oncology Hematology Care
Cincinnati, Ohio
The Ohio State University - Arthur James Cancer Hospital & Solove Research Institute
Columbus, Ohio
Mid Ohio Hem/ Onc dba The Mark H Zangmeister Center
Columbus, Ohio
Oncology Associates of Oregon (Willamette Valley Cancer Institute and Research Center)
Eugene, Oregon
Tennessee Cancer Specialists
Knoxville, Tennessee
SCRI Oncology Partners
Nashville, Tennessee
Texas Oncology - West Texas
Amarillo, Texas
Texas Oncology- Austin
Austin, Texas
Texas Oncology - Gulf Coast
Beaumont, Texas
Texas Oncology - DFW
Dallas, Texas
Texas Oncology - Northeast Texas
Denison, Texas
Texas Oncology - San Antonio
San Antonio, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Virginia Oncology Associates
Norfolk, Virginia
Blue Ridge Cancer Center (Oncology & Hematology Associates of Southwest VA)
Salem, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.